上海市肺科医院胸外科 主治医师 国际肺癌研究协会 会员 中国肿瘤临床学会 会员 Frontiers in Oncology 客座编辑 Annals of Translational Medicine 专栏编辑 Attending Surgeon, Department of Thoracic Surgery, Shanghai Pulmonary Hospital Member, International Association for the Study of Lung Cancer Member, Chinese Society of Clinical Oncology Associated Editor, Frontiers in Oncology Section Editor, Annals of Translational Medicine
第一/通讯作者（含共同）发表SCI论著27篇（近5年20篇，单篇IF最高44.544，大于10分3篇，5-10分12篇），包括J Clin Oncol, J Thorac Oncol, Ther Adv Med Oncol, Mod Pathol, Am J Surg Pathol等高水平杂志，相关成果写入中国临床肿瘤学会（CSCO）《2020CSCO 非小细胞肺癌诊疗指南》，国际肺癌研究协会（IASLC）《2017年早期肺癌诊治进展》、美国胸外科医师协会（STS）继续医学再教育CME项目（胸心外科医师必读论文）等，并被Lancet, Circulation, JACC, J Clin Oncol等权威杂志引用；主持国家自然科学基金青年项目1项及省部级课题多项，入选上海市科委“启明星计划”、市教委“晨光计划”、市卫健委“医苑新星计划”、杜克大学医学肿瘤中心Clinical Fellow（美国胸外科学会[AATS]全额资助）等；受邀赴日本呼吸器外科年会发言，并获JACS Travel Grant；获上海市抗癌科技一等奖（第3完成人）及上海市医学科技二等奖（第5完成人）。
27 SCI publications as first/corresponding author (including co-author) (20 in the past 5 years, with the highest single IF of 44.544, 3 with greater than 10, 12 with 5-10), including J Clin Oncol, J Thorac Oncol, Ther Adv Med Oncol, Mod Pathol, Am J Surg Pathol, etc. which were cited in "2020 CSCO Guidelines for the Management of Non-Small Cell Lung Cancer" by Chinese Society of Clinical Oncology (CSCO), in "2017 Advances in the Diagnosis and Treatment of Early Stage Lung Cancer" by International Association for the Study of Lung Cancer (IASLC), in Continuing Medical Education CME Program in Society of Thoracic Surgeons (STS), etc. and also cited in Lancet, Circulation, JACC, J Clin Oncol and other authoritative journals. He leads one youth project supported by National Natural Science Foundation of China and many provincial and ministerial projects, and has been selected as one of the "Rising Star" Plan of Shanghai Municipal Science Committee, "Chenguang Plan" of Municipal Education Committee, and et al. He was invited to speak at the Annual Meeting of Japanese Association of Chest Surgery in Japan and was awarded Travel Grant, and won the first prize of Shanghai Anti-Cancer Technology and second prize of Shanghai Medical Science. 代表性论著（第一/通讯[含共同]）：
1. Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J, Xie D, Fei K, Liang W, Jiang G, Yang P, Petersen RH, Ng CS, Liu CC, Rocco G, Brunelli A, Shen Y, Chen C, He J. Choice of surgical procedure for patients with non-small-cell lung cancer ≤ 1 cm or > 1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol 2016;34:3175-3182.（IF = 44.544）
2. Su H, Xie H, Dai C(co-first author), Zhao S, Xie D, She Y, Ren Y, Zhang L, Fan Z, Chen D, Jiang F, Liu J, Zhu Q, Yao J, Ke H, Zhang L, Wu C, Jiang G, Chen C. Procedure-specific prognostic impact of micropapillary subtype may guide resection strategy in small-sized lung adenocarcinomas: a multicenter study. Ther Adv Med Oncol 2020;12:1758835920937893. （IF = 8.168）
3. Dai C, Xie H, Su H, She Y, Zhu E, Fan Z, Zhou F, Ren Y, Xie D, Zheng H, Kadeer X, Chen D, Zhang L, Jiang G, Wu C, Chen C.Tumor spread through air spaces affects the recurrence and overall survival in patients with lung adenocarcinoma >2 to 3 cm. J Thorac Oncol 2017;12:1052-1060. （IF = 15.609）
4. Ren Y, Xie H, Dai C(co-first author), She Y, Su H, Xie D, Zheng H, Zhang L, Jiang G, Wu C, Chen C. Prognostic impact of tumor spread through air spaces in sublobar resection for 1A lung adenocarcinoma patients. Ann Surg Oncol 2019, 26(6):1901-1908. （IF = 5.344）
5. Dai C, Xie H, Kadeer X, Su H, Xie D, Ren Y, She Y, Zhu E, Fan Z, Chen T, Qin L, Zheng H, Zhang L, Jiang G, Wu C, Chen C. Relationship of lymph node micrometastasis and micropapillary component and their joint influence on prognosis of patients with stage I lung adenocarcinoma. Am J Surg Pathol 2017;41:1212-1220. （IF = 6.394）
6. Zhu E, Xie H, Gu C, Su H, Zhao S, Ren Y, She Y, Zheng H, Xie D, Zhu Y, Jiang G, Wu C, Dai C(co-corresponding author), Chen C. Recognition of filigree pattern expands the concept of micropapillary subtype in patients with surgically resected lung adenocarcinoma. Mod Pathol 2021, DOI: 10.1038/s41379-020-00711-8. （IF =7.842）
7. Ren Y, Zhang L, Xie H, She Y, Su H, Xie D, Zheng H, Zhang L, Jiang G, Wu C, Dai C(co-corresponding author), Chen C. Lymph node micrometastasis prognosticate survival in patients with stage 1 bronchogenic adenocarcinoma. Ann Surg Oncol 2018;25(13):3812-3819. （IF = 5.344）
8. Dai C, Ren Y, Xie D, Zheng H, She Y, Fei K, Jiang G, Chen C. Does lymph node metastasis have a negative prognostic impact in patients with NSCLC and M1a disease? J Thorac Oncol 2016;11:1745-1754.（IF = 15.609）
9. Zhu E, Dai C(co-first author), Xie H, Su H, Hu X, Li M, Fan J, Liu J, Zhu Q, Zhang L, Ke H, Chen C. Lepidic component identifies a subgroup of lung adenocarcinoma with a distinctive prognosis: a multicenter propensity-matched analysis. Ther Adv Med Oncol 2020:12, 1758835920982845. （IF = 8.168）
10. Zhu E, Xie H, Dai C(co-first author), Zhang L, Huang Y, Dong Z, Guo J, Su H, Ren Y, Shi P, Fu R, Qin S, Wu C, Chen C. Intraoperatively measured tumor size and frozen section results should be considered jointly to predict the final pathology for lung adenocarcinoma. Mod Pathol 2018;31:1391-9.（IF = 7.842）
11. Dai C, Lu Z, Zhu H, Xue S, Lian F. Bilateral internal mammary artery grafting and risk of sternal wound infection: evidence from observational studies. Ann Thorac Surg 2013;95:1938-1945（IF = 4.33）
